Rekvina Laboratories Ltd (VINRKLB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Rekvina Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Financial Result for QTR2
Intimation · 13 Nov 2026, 5:30 am
Rekvina Laboratories Schedules Board Meeting for 13th Nov'26 to Consider Q2 Results Rekvina Laboratories Limited has scheduled a meeting of its Board of Directors on 13th Nov'26 to consider and approve the unaudited Ind AS financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for designated persons has been closed from 1st Oct'26 and will reopen 48 hours after the declaration of the financial results.
Intimation regarding Temporary Shutdown of Manufacturing Facility for Renovation, Upgradation and Installation of an Additional Vial Manufacturing Line.
Others (Uncategorized) · 27 Oct 2026, 11:17 pm
Rekvina Laboratories Announces Temporary Facility Shutdown for Upgrades and Capacity Expansion Rekvina Laboratories Limited announced that its wholly owned subsidiary, Radiant Parenterals Limited, will temporarily shut down its manufacturing facility effective 28th Oct'26. The planned suspension will enable the subsidiary to execute renovation and upgradation works, alongside installing an additional vial manufacturing line to expand operations. The company stated it is taking necessary measures to ensure timely project completion and will inform stock exchanges once facility operations resume.
Appointment of Mr. Subrata Samanta as a Chief Financial officer of the company with effect from 07.10.2026.
Change in Management · 08 Oct 2026, 1:02 am
Rekvina Laboratories Appoints Subrata Samanta as Chief Financial Officer Rekvina Laboratories Limited has appointed Mr. Subrata Samanta as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective 7th Oct'26. Mr. Samanta brings over 20 years of experience in finance, costing, budgeting, taxation, and financial planning across major organizations, including GNFC, Lupin, Glenmark, Intas, and PwC. An Associate Cost and Management Accountant (ACMA) with an M.Com. from Calcutta University, his background includes SAP implementations, strategic financial management, and operational cost optimization. He has confirmed he is not debarred from holding office by SEBI.
AGM Voting Results along-with Scrutinizer Report on E-Voting
Annual General Meeting · 30 Sept 2026, 12:51 am
Summary of Proceeding of Annual General Meeting
Annual General Meeting · 29 Sept 2026, 11:21 pm
Announcement under Reg. 30 of SEBI (LODR) Regulation 2015- Noting of Resignation
Others (Uncategorized) · 24 Sept 2026, 1:20 am
Rekvina Laboratories Notes Resignation of MD Amit Shah and Relocates Registered Office Rekvina Laboratories announced that its Board of Directors approved key corporate changes on 23rd Sep'26. The Board noted the resignation of Mr. Amit Shah from his position as Managing Director, effective retroactively from 11th Sep'26, citing personal reasons and commitments. Additionally, the company approved shifting its registered office within Vadodara to 3rd Floor, 5 Laxmi Society, Old Padra Road, effective 23rd Sep'26.
Change in Registered Office w.e.f. 23.09.2026
Others (Uncategorized) · 24 Sept 2026, 1:18 am
Rekvina Laboratories Approves Office Relocation and Managing Director Resignation Rekvina Laboratories Limited's Board of Directors approved the relocation of its registered office within Vadodara to Laxmi Society, Old Padra Road, effective 23rd Sep'26. Additionally, the Board noted the resignation of Managing Director Amit Shah (DIN: 01993211), effective 11th Sep'26, citing personal reasons and commitments. Shah holds no other listed directorships or committee positions, and has no disclosed relationships with remaining directors.
Resignation of Mr. Amit Shah from the Position of Managing Director and Director of the company w.e.f. 11.09.2026.
Change in Management · 12 Sept 2026, 10:22 pm
Rekvina Laboratories MD Amit Mukesh Shah Resigns Due to Personal Commitments Rekvina Laboratories Limited announced that Amit Mukesh Shah has resigned from his position as Managing Director and Director of the company, effective 11th Sep'26. The departure is attributed entirely to personal reasons and personal commitments, with the executive confirming that no other material factors prompted his decision to step down from the board.
Annual Report FY2526
Others (Uncategorized) · 03 Sept 2026, 9:07 pm
Shareholder''s Meeting to be held on 29.09.2026 through online mode
Annual General Meeting · 03 Sept 2026, 9:02 pm
Rekvina Laboratories Announces 38th AGM, Director Appointments, and Officer Resignation Rekvina Laboratories will hold its 38th AGM virtually on 29th Sep'26 to adopt FY26 financials and confirm key leadership changes. Shareholders will vote on re-appointing Director Ilaben Pathak and approving five-year terms for Independent Directors Prateek Jain and Jay Chintan Patel. Additionally, the Board accepted Company Secretary Deepak Khandelwal's resignation effective 2nd Sep'26, and appointed Hetanshi Shah & Associates as Internal Auditor. The company's share transfer books will close from 23rd Sep'26 to 29th Sep'26, with the remote e-voting cut-off date set for 22nd Sep'26.
Resignation of Mr. Deepak Khandelwal from the position of Company Secretary and Compliance Officer
Change in Management · 03 Sept 2026, 1:06 am
Rekvina Laboratories Announces Resignation of Company Secretary Deepak Khandelwal Rekvina Laboratories Limited (BSE: 526075) announced the resignation of Mr. Deepak Khandelwal as Company Secretary and Compliance Officer, effective 2nd Sep'26. The departure of the Key Managerial Personnel is attributed to personal reasons. Khandelwal has requested the immediate settlement of his outstanding salary and dues while committing to a smooth handover of statutory records and responsibilities. The company will now proceed with necessary regulatory filings to formalize this administrative transition and initiate the search for a new compliance leader.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Surbhit Mukesh Shah & Others
Acquisition/ Disposal of Shares · 18 Aug 2026, 4:11 pm
Rekvina Labs: Promoter Group Hikes Stake to 60.30% via Preferential & Open Offer Promoter group Surbhit Mukesh Shah and Persons Acting in Concert (PACs) increased their total shareholding in Rekvina Laboratories to 60.30% from a pre-acquisition stake of 28.96%. The acquisition involved a preferential allotment on 12th Aug'26 and an open offer on 13th Aug'26. Consequently, the company's total voting capital increased from ₹3.01cr to ₹5.56cr. Surbhit Mukesh Shah and Amit Mukesh Shah now hold 27.15% each. The acquisition was for consideration other than cash via a share swap agreement.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhruvalkumar Patel
Acquisition/ Disposal of Shares · 17 Aug 2026, 8:45 pm
Insider Dhruvalkumar Patel Acquires 10% Stake in Rekvina Laboratories Dhruvalkumar Patel, classified as an acquirer, has acquired 11,12,562 equity shares in Rekvina Laboratories Ltd., representing a 10.01% stake. The acquisition, disclosed on 17 Aug'26, was executed via an open offer and a preferential allotment. This transaction increases the company's total voting capital to ₹5.56 crore. Prior to this, the acquirer held no shares. The acquisition was made for consideration other than cash via a share swap.
Clarification on Price Movement
Others (Uncategorized) · 15 Aug 2026, 1:06 am
Rekvina Laboratories Clarifies Recent Share Price Movement In a 14 Aug'26 filing with the BSE, Rekvina Laboratories responded to a query regarding significant price movement in its securities. The company stated it is not aware of any undisclosed price-sensitive information, event, or development that could be affecting the stock. Rekvina confirmed compliance with all SEBI disclosure obligations and asserted that the recent price and volume action is purely market-driven. The company affirmed it has no specific information or comment on the market activity and has not withheld any material information.
FINANCIAL RESULT QTR1
Financial Result · 13 Aug 2026, 9:26 pm
Rekvina Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lacs) ■ Revenue: 66.9 (Negative to Positive YoY | -7.6% QoQ) ■ EBITDA: -18.1 (-155.6% YoY | -49.6% QoQ) ■ EBITDA Margin (%): -27.1 (Profit to Loss YoY | -1035 bps QoQ) ■ PAT: -12.1 (-240.4% YoY | -99.2% QoQ) ■ EPS (INR): -0.20 (-233.3% YoY | -100.0% QoQ)
OUTCOME OF BOARD MEETING
Outcome · 13 Aug 2026, 9:17 pm
Rekvina Labs Reports Wider Q1FY27 Loss; Appoints New Chairman Rekvina Laboratories reported Q1FY27 standalone results, with revenue declining 7.6% QoQ to ₹66.85 lacs. The net loss widened to ₹12.05 lacs from ₹6.05 lacs in Q4FY26 and ₹3.54 lacs in Q1FY26, driven by higher expenses. EPS for the quarter was -₹0.20. The Board approved the results and the appointment of Mr. Surbhit Shah as Executive Director and Chairman, effective 13th Aug'26. The statutory auditors issued an unmodified limited review report on the financials for the quarter ended 30th Jun'26.
The Exchange has sought clarification from Rekvina Laboratories Ltd on August 12, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 12 Aug 2026, 11:29 pm
Allotment of Equity Shares on Preferential basis
Others (Uncategorized) · 12 Aug 2026, 10:57 pm
Rekvina To Acquire Radiant Parenterals, Issues Preferential Shares On 12-Aug'26, Rekvina Laboratories approved a two-part preferential allotment. First, it will issue 46.28M shares at ₹10/share for a non-cash consideration of ₹4.63Cr to fully acquire Radiant Parenterals, a pharmaceutical firm with FY25 revenue of ₹31.67Cr. This share swap makes Radiant a wholly-owned subsidiary. Second, it will issue 0.46M shares at ₹10/share to non-promoters, raising ₹46L in cash. Total new shares issued will be 50.88M. Post-allotment, the promoter group's shareholding will increase from 28.96% to 57.34%.
Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Unaudited Financcial Result ....
Intimation · 13 Aug 2026, 5:30 am
Rekvina Laboratories Board Meeting on 13 Aug'26 for Q1 Results Rekvina Laboratories (BSE: 526075) has scheduled a Board of Directors meeting on 13 Aug'26 to consider and approve the un-audited standalone financial results for the quarter ended 30 Jun'26. In connection with the results, the trading window for designated persons has been closed from 01 Jul'26 until 48 hours after the financial results are publicly announced.
Post offer Newspaper Annoucement
Others (Uncategorized) · 01 Aug 2026, 5:47 pm
Rekvina Laboratories Open Offer Concludes, Acquirers Secure 64.30% Stake Surbhit Mukesh Shah and two other acquirers concluded their open offer for Rekvina Laboratories, which ran from 01 Jul'26 to 14 Jul'26. The offer, priced at ₹10/- per share, was partially successful, with 14,41,863 shares accepted against the 28,90,100 shares offered. Post-offer, the acquirer and PAC group's shareholding increased from a pre-agreement 28.96% to 64.30% of the expanded share capital. Correspondingly, public shareholding has decreased from 58.70% to 23.00% following the transaction.
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post Offer Advertisement in accordance with Regulation 18(12) of the Securities Exchange Board ....
Others (Uncategorized) · 31 Jul 2026, 7:21 pm
Rekvina Labs Open Offer Update: Acquirers' Post-Offer Stake at 64.30% Following the open offer for Rekvina Laboratories by Surbhit Shah and others, the acquirers accepted 14,41,863 shares out of 28,90,100 tendered at ₹10 per share. The offer closed on 14th Jul'26. Post-acquisition, the acquirers' and PACs' collective shareholding increased from 28.96% to 64.30% of the expanded share capital, below the proposed 77.33% level assuming full acceptance. Consequently, the public shareholding decreased from 58.70% to 23.00%. The acquisition also involved a share purchase agreement dated 16th Mar'26.
Open Offer Update
Others (Uncategorized) · 01 Jul 2026, 12:19 am
Acquirers Launch Open Offer for 26% Stake in Rekvina Laboratories An open offer has been announced for the acquisition of up to 2,890,100 equity shares of Rekvina Laboratories, representing 26% of the company's voting share capital. The offer is made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The offer price is set at ₹10 per share. Key dates have been revised, with the new offer opening on Jul 14, '26, and closing on Jul 27, '26. The announcement follows a share purchase agreement executed on Mar 16, '26.
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of The Securities and Exchange ....
Others (Uncategorized) · 01 Jul 2026, 12:06 am
Rekvina Laboratories Open Offer for 26% Stake at ₹10 Per Share Surbhit Shah, Amit Shah, and Dhruvalkumar Patel launched an open offer to acquire up to 28,90,100 equity shares of Rekvina Laboratories, representing 26% of its expanded share capital. The offer price is ₹10 per share. The offer’s tendering period is scheduled from 01 Jul’26 to 14 Jul’26. The target company’s Committee of Independent Directors deemed the offer price fair and reasonable. This action is pursuant to SEBI's SAST regulations and is managed by Vivro Financial Services Private Limited.
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Recommendations of the Committee of Independent Directors in accordance with Regulation 26(7) ....
Others (Uncategorized) · 25 Jun 2026, 7:58 pm
Rekvina Laboratories Open Offer: Independent Directors Note Significant Price Discount Rekvina Laboratories' Independent Directors' Committee (IDC) has deemed the open offer price of ₹10 per share as fair and reasonable under SEBI regulations. The offer is for the acquisition of up to 28,90,100 equity shares (26% of expanded capital) by Surbhit Mukesh Shah and others. However, the IDC highlighted that the offer price is substantially lower than the closing market price of ₹37.45 on BSE as of Jun 23, '26. Shareholders are advised to independently evaluate the offer before making a decision.
Newspaper Advertisement
Others (Uncategorized) · 25 Jun 2026, 7:42 pm
Rekvina Labs: Independent Directors Find ₹10 Open Offer Price Fair but Below Market Rekvina Laboratories' Independent Directors' Committee (IDC) has deemed the open offer price of ₹10 per share as fair and reasonable. The offer, by Surbhit Shah and others, is for up to 28,90,100 shares (26% of equity). The IDC notes the price is significantly below the closing market price of ₹37.45 on the BSE as of 23 Jun'26. While finding the price compliant with SEBI regulations, the committee advises shareholders to independently evaluate the offer, considering the substantial discount to the prevailing market rate before making a decision.